Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation and backed by Blackstone Life Sciences, today announced the appointment of Will Kane as President and CEO ...

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Incyte named former Karuna Therapeutics and Anthos Therapeutics exec Bill Meury as CEO. Vistagen appoints Elissa Cote as chief corporate development officer. Inizio Evoke, a 2025 MM+M Agency 100 ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.